Thu, Jun 14, 2012 2:13 PM
Clinical trial results of biosimilar infliximab
Results of clinical trials conducted on biosimilar infliximab have been disclosed.

Egis Pharmaceuticals PLC (the 'Company', having its headquarters at H-1106 Budapest, Keresztúri út 30-38.), in effort to meet the rules set in point (9) Section 54 of the modified Capital Market Act (CXX/2001), hereby publishes the following information on voting rights attached to its shares and on the share capital.

Related file

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox